NCT00886353View on ClinicalTrials.gov

Safety and Tolerability Study of APN01 (Recombinant Human Angiotensin Converting Enzyme 2)

PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

April 30, 2009

Primary Completion Date

November 30, 2009

Study Completion Date

December 31, 2009

Conditions
Pulmonary DiseasesCardiovascular DiseasesKidney DiseasesCancer Diseases
Interventions
BIOLOGICAL

APN01

APN01, a physiological formulation of recombinant human Angiotensin Converting Enzyme 2 administrated i.v.

OTHER

Placebo

Physiological saline administrated i.v.

Trial Locations (1)

4031

University Hospital Basel, Basel

Sponsors

Lead Sponsor

Apeiron Biologics
All Listed Sponsors
lead

Apeiron Biologics

INDUSTRY

NCT00886353 - Safety and Tolerability Study of APN01 (Recombinant Human Angiotensin Converting Enzyme 2) | Biotech Hunter | Biotech Hunter